Mitomycin: Side Effects, Uses & Monitoring
Mitomycin for Injection, USP is not recommended as single-agent, primary therapy.
- Data source
- FDA labeling via NIH DailyMed (label 6a4fbc96…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
Mitomycin for Injection, USP is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy.
Frequently Asked Questions
What is Mitomycin used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Mitomycin?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Mitomycin require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Mitomycin.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.